10 Aug Amphivena Therapeutics Announces Acceptance of Investigational New Drug (IND) Application for AMV564 and Planned Phase 1 Trial Initiation
Proprietary T-cell Redirecting Bispecific CD33/CD3 Antibody for the Treatment of AML Nears First-in-Human Study SAN FRANCISCO, CA, August 10, 2016 --- Amphivena Therapeutics, Inc., a developer of cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND)...